Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
spartalizumab + paclitaxel + carboplatin
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination regimen consisting of **spartalizumab** (a humanized monoclonal antibody targeting Programmed Death-1 [PD-1]), **paclitaxel** (a microtubule-stabilizing cytotoxic chemotherapeutic agent), and **carboplatin** (a platinum-based DNA-damaging cytotoxic chemotherapeutic). This combination is under clinical investigation for use in advanced solid tumors such as non-small cell lung cancer (NSCLC) and potentially other cancers. Spartalizumab blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2), thereby enhancing antitumor T cell responses by relieving PD-1 mediated immune suppression. Paclitaxel inhibits cell division by stabilizing microtubules and preventing their depolymerization, while carboplatin promotes DNA crosslinking and damages tumor cell DNA, resulting in cell death. Preclinical and early phase clinical results suggest this combination is tolerable and shows activity in platinum-doublet chemotherapy regimens for cancers including NSCLC[1][8].
- Other names
- spartalizumab + paclitaxel + carboplatin
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on spartalizumab + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on spartalizumab + paclitaxel + carboplatin.